Replies to post #205362 on Biotech Values

[DewDiligence]

ADXS/MRK—Dosing during the phase-2 portion of the study:

https://www.clinicaltrials.gov/ct2/show/NCT02325557

Patients will receive ADXS31-142 and pembrolizumab [Keytruda] in combination. Dosing of ADXS31-142 will start at one dose level less than appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate.